AstraZeneca advances scientific leadership across multiple cancers with first data from four pivotal Phase III trials at ESMO

Two highly anticipated Presidential Symposia for TROPION-Lung01 and TROPION-Breast01
will unveil the significance of datopotamab deruxtecan in lung and breast cancers

FLAURA2 data reinforce Tagrisso as the backbone therapy in EGFR-mutated lung
cancer and underscore its added benefit of treating brain metastases

DUO-E results for Imfinzi plus Lynparza will show the benefit of immunotherapy
and PARP inhibitor combinations in endometrial cancer for the first time

First Imfinzi data in gastric cancer from MATTERHORN Phase III trial will highlight the
potential of immunotherapy combinations in earlier settings and growing leadership
in gastrointestinal cancers

/Public Release. View in full here.